Get to know our clinical trials

Trial to evaluate the safety and pharmacokinetics of BTCT4465A in monotherapy and combination with atezolizumab in patients with relapsed or refractory non-Hodgkin B-lymphocyte lymphoma and chronic lymphocytic leukemia.

Navarre headquarters
Madrid headquarters
Diseases
Leucemia
Linfoma
Leucemia linfática crónica
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • MULTICENTER, UNBLINDED PHASE I/IB TRIAL TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A IN MONOTHERAPY AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S B-LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA.
  • Code EudraCT: 2017-003267-35
  • Protocol number: GO29781
  • Promoter: Genentech, Inc.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.